Mpox (Monkeypox) Vaccine
Mpox (Monkeypox) · Smallpox (ACAM2000)
Mpox is a zoonotic viral disease caused by the monkeypox virus (genus Orthopoxvirus). It causes fever, swollen lymph nodes, and a characteristic rash that progresses from flat lesions to deep, painful pustules. The 2022 global outbreak (clade IIb) spread primarily through close skin-to-skin contact. Clade I, endemic to Central Africa, has higher mortality (~1–10%).
Overall Benefit Score
Default scenario · 12-month-old · US community (92% vax rate)
Score for your child →Worth careful consideration. Disease risk in your scenario is lower than average, or the vaccine risk/uncertainty is somewhat higher. Discuss timing and priorities with your provider.
📊 Evidence Scores
Scores computed from peer-reviewed data using VaxFact's evidence model. Based on default scenario (12-month-old, standard US community).
🦠 Disease Burden
Mpox is a zoonotic viral disease caused by the monkeypox virus (genus Orthopoxvirus). It causes fever, swollen lymph nodes, and a characteristic rash that progresses from flat lesions to deep, painful pustules. The 2022 global outbreak (clade IIb) spread primarily through close skin-to-skin contact. Clade I, endemic to Central Africa, has higher mortality (~1–10%).
The rash is intensely painful, especially when lesions appear on the face, genitals, anus, or mouth. Healing takes 2–4 weeks. Complications include bacterial superinfection, scarring, encephalitis, and eye involvement that can cause blindness. Patients describe the experience as profoundly debilitating. Stigma and social isolation compound the psychological burden.
🛡️ Vaccine Effectiveness
JYNNEOS (2-dose subcutaneous series) showed 86% effectiveness in the 2022 outbreak per CDC studies. Immunity is expected to last years based on smallpox vaccine analogy but long-term data for mpox specifically are still accumulating. A single dose provides substantial but partial protection.
Breakthrough infections reported but generally milder. Most breakthrough cases involve incomplete vaccination (1 dose). Vaccination after exposure (within 4 days) can prevent illness; within 14 days can reduce severity.
⚠️ Adverse Events & Side Effects
All probabilities are per 100,000 doses administered, sourced from VAERS, Vaccine Safety Datalink, and post-licensure surveillance studies.
Common Side Effects
Rare Serious Events
📅 Vaccine Schedule
Single dose provides meaningful protection if 2-dose series cannot be completed before exposure. Post-exposure prophylaxis (PEP): 2 doses within 14 days of exposure. ACAM2000 is single-dose but contraindicated in immunocompromised and cardiac patients.
⚖️ Benefits vs. Considerations
✓ Benefits
- 86% effectiveness against mpox infection demonstrated in the 2022 real-world outbreak
- JYNNEOS is a replication-deficient vaccine — cannot cause mpox or vaccinia disease
- Also provides protection against smallpox (dual benefit given bioterrorism risk)
- Post-exposure prophylaxis: vaccination within 4 days of exposure can prevent illness
- Well-tolerated with primarily mild, injection-site reactions
↕ Considerations
- Requires 2 doses 4 weeks apart for full protection
- Currently recommended only for at-risk populations, not universal
- Limited long-term data on duration of immunity (field use began 2022)
- ACAM2000 (alternative) is a live virus vaccine with more significant side effects
- Supply constraints have limited access in outbreak settings
🔬 What Some Researchers Question
These are legitimate scientific debates — not fringe claims. They represent areas of ongoing research or policy disagreement among credentialed experts.
- Some researchers argue the risk-stratified approach (vaccinating only 'at-risk' populations) creates stigma and misses transmission chains in heterosexual networks and close household contacts (Thornhill et al., 2022).
- The emergency authorization and accelerated rollout in 2022 meant post-market data were collected rapidly under outbreak conditions, making it harder to disentangle vaccine effects from behavioral changes during the outbreak.
🌫️ Scientific Uncertainties
Honest acknowledgment of what we don't yet know with confidence.
- Duration of immunity from JYNNEOS — long-term follow-up studies ongoing
- Whether a single dose provides sufficient protection in high-exposure settings
- Effectiveness against Clade I mpox (more virulent Central African strain), which is causing new outbreaks
- Whether population-level vaccination of at-risk groups can interrupt transmission and prevent future outbreaks
🌍 International Policy Comparison
How different countries approach this vaccine — revealing where global consensus is strong vs. where policy diverges.